NFE2L2 and type 2 diabetes mellitus: Similarly, bardoxolone methyl, a synthetic triterpenoid that activates Nrf2, has been tested in patients with diabetic nephropathy (NCT00664027, phase II), pulmonary hypertension (NCT03068130, phase III) or in chronic kidney disease/type 2 diabetes (NCT00811889, phase II).